NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
SHELTON, Conn., Sept. 14, 2021 /PRNewswire/ — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), a global leader in nanomedicines against viruses, announced today that it has completed the process of licensing the human Coronavirus field for drug development and commercialization…
Comments Off on NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development